Literature DB >> 28364990

Polypharmacy Reduction Strategies: Tips on Incorporating American Geriatrics Society Beers and Screening Tool of Older People's Prescriptions Criteria.

Hedva Barenholtz Levy1.   

Abstract

There is no single definition of polypharmacy. Use of 5 or more medications commonly is used. An alternative, quantitative definition, such as use of more medications than clinically indicated or use of unnecessary or harmful prescribing, has been proposed. Protocols or algorithms to improve polypharmacy and prescribing in older adults have been developed. The American Geriatrics Society (AGS) Beers Criteria and Screening Tool of Older People's Prescriptions (STOPP) explicit criteria reflect elements that are common across protocols and algorithms. Concepts in AGS Beers and STOPP can be incorporated into polypharmacy reduction strategies to improve outcomes of care for older adults.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aged/aging; Explicit criteria; Medication use; Polypharmacy; Potentially inappropriate medications; Prescribing

Mesh:

Year:  2017        PMID: 28364990     DOI: 10.1016/j.cger.2017.01.007

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN: 0749-0690            Impact factor:   3.076


  14 in total

Review 1.  Machine Learning to Predict, Detect, and Intervene Older Adults Vulnerable for Adverse Drug Events in the Emergency Department.

Authors:  Kei Ouchi; Charlotta Lindvall; Peter R Chai; Edward W Boyer
Journal:  J Med Toxicol       Date:  2018-06-01

Review 2.  Inhibiting Cellular Senescence: A New Therapeutic Paradigm for Age-Related Osteoporosis.

Authors:  Sundeep Khosla; Joshua N Farr; James L Kirkland
Journal:  J Clin Endocrinol Metab       Date:  2018-04-01       Impact factor: 5.958

3.  Managing Nocturia in Frail Older Adults.

Authors:  Dylan T Wolff; Kerry A Adler; Corey S Weinstein; Jeffrey P Weiss
Journal:  Drugs Aging       Date:  2020-11-24       Impact factor: 3.923

Review 4.  The role of senolytics in osteoporosis and other skeletal pathologies.

Authors:  Madison L Doolittle; David G Monroe; Joshua N Farr; Sundeep Khosla
Journal:  Mech Ageing Dev       Date:  2021-09-06       Impact factor: 5.498

5.  Effect of an In-Hospital Multifaceted Clinical Pharmacist Intervention on the Risk of Readmission: A Randomized Clinical Trial.

Authors:  Lene Vestergaard Ravn-Nielsen; Marie-Louise Duckert; Mia Lolk Lund; Jolene Pilegaard Henriksen; Michelle Lyndgaard Nielsen; Christina Skovsende Eriksen; Thomas Croft Buck; Anton Pottegård; Morten Rix Hansen; Jesper Hallas
Journal:  JAMA Intern Med       Date:  2018-03-01       Impact factor: 21.873

Review 6.  The role of cellular senescence in ageing and endocrine disease.

Authors:  Sundeep Khosla; Joshua N Farr; Tamara Tchkonia; James L Kirkland
Journal:  Nat Rev Endocrinol       Date:  2020-03-11       Impact factor: 43.330

7.  The application of updating PIM-Taiwan criteria in clinic-visiting older patients with polypharmacy.

Authors:  Chirn-Bin Chang; Hsiu-Yun Lai; Shinn-Jang Hwang; Shu-Yu Yang; Ru-Shu Wu; Hsing-Cheng Liu; Ding-Cheng Chan
Journal:  Ther Adv Drug Saf       Date:  2018-10-15

8.  A nationwide survey of hospital pharmacist interventions to improve polypharmacy for patients with cancer in palliative care in Japan.

Authors:  Mayako Uchida; Shinya Suzuki; Hideki Sugawara; Yukio Suga; Hideya Kokubun; Yoshihiro Uesawa; Takayuki Nakagawa; Hisamitsu Takase
Journal:  J Pharm Health Care Sci       Date:  2019-07-03

9.  Prevalence and impact of potentially inappropriate medication on community-dwelling older adults.

Authors:  Alejandra Fernández; Fernando Gómez; Carmen-Lucía Curcio; Edison Pineda; Juliana Fernandes de Souza
Journal:  Biomedica       Date:  2021-03-19       Impact factor: 0.935

10.  Polypharmacy, hospitalization, and mortality risk: a nationwide cohort study.

Authors:  Tae Ik Chang; Haeyong Park; Dong Wook Kim; Eun Kyung Jeon; Connie M Rhee; Kamyar Kalantar-Zadeh; Ea Wha Kang; Shin-Wook Kang; Seung Hyeok Han
Journal:  Sci Rep       Date:  2020-11-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.